Gilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...

MIT researchers have developed a new HIV vaccination method that generates a strong immune response with just two doses, one ...

Lenacapavir, a new HIV prevention drug, has proven to dramatically reduce the risk of infection according to data reported ...

Efavirenz is an important drug for treating HIV infection, but it has negative effects that can significantly impact patients ...

One major reason why it has been difficult to develop an effective HIV vaccine is that the virus mutates very rapidly, ...

A drug currently used to treat HIV has also been found to dramatically reduce the risk of infection, significantly more than ...

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating ...

Potential to revolutionize HIV prevention. Ethel Weld, an Assistant Professor of Medicine at Johns Hopkins University School ...

Nobody has ever contracted HIV or hepatitis from toilet roll, as the viruses don't survive for long outside the body.

Drugmaker Gilead has announced that its new, twice-a-year shot of lenacapavir reduced HIV infections by 96% in a Phase 3 clinical trial. The company wi ...

Researchers at Université de Montréal's affiliated hospital research center, the CRCHUM, say the discovery could help lessen ...

Progress in preventing infections was being made in the country with Europe's second-highest number of HIV cases. Then came ...